SOHO 2026 | NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera
• 14 Sep 2026
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL). Prof. Ribera highlights that combining NGS-MRD assessment with the genetic basis of the disease may help guide treatment selection and support the use of targeted therapies in specific ALL subtypes. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
